By Shreyashi Sanyal and Krystal Hu (Reuters) - The Dow Jones Industrial Average closed at a record high on Thursday, bolstered by an upbeat weekly jobless claims report, while...
By Mrinalika Roy and Manojna Maddipatla (Reuters) -Regeneron Pharmaceuticals Inc reported a better-than-expected quarterly profit on Thursday and said it expects demand for its...
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned $9.89 per share for the first quarter, beating the $9.03 estimate. Revenue of $2.53 billion narrowly missed analyst consensus of...
Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. REGN reported strong growth in earnings and sales in the first quarter of 2021 on broad-based portfolio growth. Evidently, shares are...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Neutral |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,337.35 | 2,337.35 | 2,293.04 | +22.58 | +0.98% | 1.26M | NASDAQ | |||
| 320.02 | 320.24 | 313.28 | +5.00 | +1.59% | 19.01M | NASDAQ | |||
| 152.85 | 159.13 | 150.00 | -14.30 | -8.56% | 2.55M | NYSE | |||
| 67.53 | 68.50 | 65.01 | +4.46 | +7.07% | 12.59M | NYSE | |||
| 52.17 | 52.25 | 48.24 | +2.09 | +4.17% | 3.59M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 332.66 | 343.08 | 328.24 | -22.83 | -6.42% | 818.70K | NASDAQ | |||
| 7.59 | 7.71 | 7.34 | +0.29 | +3.97% | 16.22M | NYSE | |||
| 1.15 | 1.22 | 1.11 | -0.0500 | -4.17% | 21.94M | NYSE | |||
| 141.30 | 141.55 | 139.23 | +2.42 | +1.74% | 743.54K | NYSE | |||
| 15.93 | 16.29 | 15.02 | +0.99 | +6.63% | 8.64M | NYSE | |||
| 0.8223 | 0.00 | 0.00 | +0.0228 | +2.85% | 3.71M | NYSE | |||
| 226.42 | 228.44 | 222.88 | -0.36 | -0.16% | 12.25M | NYSE | |||
| 33.45 | 36.649 | 32.00 | -3.170 | -8.66% | 14.60M | NASDAQ | |||
| 58.00 | 58.96 | 58.00 | 0.00 | 0.00% | 0.00 | NYSE |
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.